Actavis May Need To Rethink Nebivolol/Valsartan Claim After Negative Panel Vote
This article was originally published in The Pink Sheet Daily
The sponsor argues that the fixed-dose antihypertensive combo offers better efficacy and tolerability than either compound as solo therapy, but FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 6-4 against approval.
You may also be interested in...
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
The goal is to create a program which mass sequences SARS-CoV-2 samples in order to detect new variants, with £30m injected into the UK's hub for genomic sequencing in Cambridge.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.